Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB, TrkC or Flt-3 thereby making them useful as anticancer agents.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: The invention relates to 4-chloro-2-iodopyrrolo[1,2-f][1,2,4]triazine, which is an intermediate useful in preparing 2,4-disubstituted pyrrolotriazine compounds, and a process for preparing said intermediate.

Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB, TrkC or Flt-3 thereby making them useful as anticancer agents.

Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB, TrkC or Flt-3 thereby making them useful as anticancer agents.

Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Abstract: A stowable wing structure incorporates a wing having a span equal to a fuselage length and movable from a stowed position longitudinally aligned with the fuselage to a deployed position perpendicular to the fuselage. A pivot offset laterally from a centerline of the fuselage and aft from a symmetry point on the centerline with a corresponding offset forward toward the leading edge from a chord centerpoint on the wing allows rotation of the wing from the stowed position to the deployed position with the rotation resulting in an aft position of the chord center point relative to the fuselage symmetry point.

Abstract: The present invention is directed to compounds having the formula (I), and/or pharmaceutically-acceptable salts thereof, useful in the treatment of androgen-receptor associated conditions, wherein Ar is aryl, substituted aryl, heteroaryl, or substituted heteroaryl; L is a linker as defined in the specification; R1 may be hydrogen, cyano, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclo, substituted heterocyclo, heteroaryl, or substituted heteroaryl, as defined in the specification; R2 is hydrogen, lower alkyl, or substituted lower alkyl; and R3, R4 and R5 are optionally non-interfering substituents as defined in the specification.

Abstract: A process for establishing manufacturing parameters includes computer simulating a manufacture of a laser-sintered part based on a set of manufacturing parameters, calculating a set of physical properties of the simulated manufacture, and modifying the set of manufacturing parameters based on the calculated set in order to obtain a desired set of physical properties.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB, TrkC or Flt-3 thereby making them useful as anticancer agents.

Abstract: The invention relates to 2,4-dibromoropyrrolo[1,2-f][1,2,4]triazine, which is an intermediate useful in preparing 2,4-disubstituted pyrrolotriazine compounds, and a process for preparing the intermediate.

Abstract: A stowable wing structure incorporates a wing having a span equal to a fuselage length and movable from a stowed position longitudinally aligned with the fuselage to a deployed position perpendicular to the fuselage. A pivot offset laterally from a centerline of the fuselage and aft from a symmetry point on the centerline with a corresponding offset forward toward the leading edge from a chord centerpoint on the wing allows rotation of the wing from the stowed position to the deployed position with the rotation resulting in an aft position of the chord center point relative to the fuselage symmetry point.

Abstract: A process of for creating process build parameters includes creating a set of process build parameters for laser-sintering of a part based on a thermal model of a parts bed of a laser sintering machine and empirical data from prior laser-sintered parts built in the parts bed.

Abstract: A negative pressure wound therapy apparatus includes a wound dressing for forming a substantially fluid-tight seal over a wound to define a reservoir over the wound in which a negative pressure may be maintained. A vacuum source is in fluid communication with the reservoir to provide an appropriate negative pressure to the reservoir to stimulate healing of the wound. The apparatus includes a fluid conduit in fluid communication with the reservoir and defining a fluid flow path for carrying fluids from the reservoir, and a fluid line coupling adapted for selective engagement and disengagement of first and second coupling segments to respectively maintain and interrupt the fluid flow path.

Abstract: Slurry fuels and associated methods are disclosed herein. One aspect of the invention is directed toward a slurry fuel that includes a liquid hydrocarbon based fuel suitable for use in an air-breathing power plant, metallic particles (e.g., boron), and a fluoropolymer (e.g., polytetrafluoroethylene). In selected embodiments the slurry fuel can further include a surfactant (e.g., polyolefin amide alkeneamine and/or Product NB463S84 produced by GE Betz, Inc.). Other aspects of the invention are directed toward a slurry fuel that includes a liquid hydrocarbon based fuel, metallic particles, and a surfactant having a composition that lowers the surface tension of the liquid hydrocarbon based fuel and reduces the tendency for the metallic particles to separate from the liquid hydrocarbon based fuel.